Glidewell Publishes Inaugural Edition of Integrate(TM) Magazine
A new publication dedicated to making implant dentistry more accessible to all.NEWPORT BEACH, CA / ACCESSWIRE / January 5, 2024...
Year: 2024
Spiden Announces Breakthrough in Non-Invasive Glucose Monitoring, Adds Key Executive Hires and Secures $15m in Additional Funding
PFÄFFIKON, SWITZERLAND / ACCESSWIRE / January 5, 2024 / Spiden, a pioneer in non-invasive biomarker monitoring technology, is thrilled to...
Nutriband Signs Commercial Development and Clinical Supply Agreement With Kindeva Drug Delivery for Aversa(TM) Fentanyl, an Abuse Deterrent Fentanyl Patch
ORLANDO, FL / ACCESSWIRE / January 5, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of transdermal...
AngioDynamics Reports Fiscal Year 2024 Second Quarter Financial Results; Revises Fiscal Year 2024 Guidance
Fiscal Year 2024 Second Quarter Highlights Net sales of $79.1 million increased 2.7% on a pro-forma basis compared to the...
Metrodora Institute Announces New Chief Scientific Officer
Rohit Gupta, a Nationally Recognized Scientist, Biobank and Data Expert, is Named as Metrodora Institute's New Chief Scientific Officer and...
Zen Dog Veterinary Care Expands Services to Westchester
NEW YORK, NY / ACCESSWIRE / January 5, 2024 / Zen Dog Veterinary Care, New York City's premier in-home pet...
CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform
Head-to-head comparison with licensed bivalent mRNA-based comparator vaccine confirms competitive immune responses at lower doses and favorable tolerability profileMonovalent mRNA...
Standard BioTools Completes Merger with SomaLogic, Creating a Diversified and Scaled Leader in Life Sciences Tools
Establishes Leading Platform of Complementary Multi-omic Technologies with Enhanced Scale and Commercial Reach; Strengthened Balance Sheet to Self-Fund Future Growth...
Jasper Therapeutics Highlights Recent Accomplishments and Key Upcoming Milestones
- EU Clinical Trials authorized for Phase 1b/2a SPOTLIGHT and BEACON studies of briquilimab in CIndU and CSU, respectively -...
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference, January 25 – 27, in Milan, Italy
JERSEY CITY, N.J., Jan. 05, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to...
Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea
If approved, DFD-29 has potential to be best-in-class and the only oral medication to address both inflammatory lesions and erythema...
NurExone Announces Closing of a Private Placement for Gross Proceeds of Approximately CAD$2 Million
TORONTO and HAIFA, Israel , Jan. 05, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the...
Healthcare Triangle, Inc. to Participate at the 2024 MUSE Executive Institute
PLEASANTON, Calif., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Healthcare Triangle, Inc. (Nasdaq: HCTI) (“Healthcare Triangle,” “HCTI” or the “Company”), a leader...
Axial Therapeutics to Present at Upcoming Conferences
WOBURN, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Axial Therapeutics, a clinical-stage biotechnology company dedicated to the development of gut-targeted,...
Spero Therapeutics Provides Corporate Update and 2024 Outlook
In 2H 2024, expect to provide Phase 2a topline proof-of-concept data from our wholly-owned lead program SPR720 in NTM-PD patients...
Catalyst Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock
CORAL GABLES, Fla., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or the “Company”) (Nasdaq: CPRX) announced today...
Mersana Therapeutics Announces Business Updates, Expected 2024 Milestones and Upcoming Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
Enrollment in dose escalation and backfill cohorts continuing in Phase 1 clinical trial of XMT-1660, Dolasynthen B7-H4 ADC; expect to...
MAPS Welcomes New Investors, Name Change for MAPS Public Benefit Corporation
Lykos Therapeutics, formerly known as MAPS PBC, announced the close of Series A financing to support regulatory and pre-launch activities...
Prime Medicine Appoints Allan Reine, M.D., as Chief Financial Officer
CAMBRIDGE, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a...
Smart for Life Announces Completion of Audit for Pending Acquisition
Acquisition Expected to Contribute More than $8 Million of Annualized Revenue and Positive Net IncomeMIAMI, Jan. 05, 2024 (GLOBE NEWSWIRE)...